FY2025 Earnings Forecast for MRSN Issued By Leerink Partnrs

Mersana Therapeutics, Inc. (NASDAQ:MRSN) – Analysts at Leerink Partnrs cut their FY2025 earnings per share estimates for shares of Mersana Therapeutics in a research note issued on Monday, March 3rd. Leerink Partnrs analyst J. Chang now anticipates that the company will earn ($0.63) per share for the year, down from their previous estimate of ($0.43). The consensus estimate for Mersana Therapeutics’ current full-year earnings is ($0.62) per share. Leerink Partnrs also issued estimates for Mersana Therapeutics’ FY2026 earnings at ($0.18) EPS.

A number of other research analysts have also recently issued reports on MRSN. William Blair began coverage on shares of Mersana Therapeutics in a research report on Thursday, February 6th. They set an “outperform” rating for the company. Wedbush restated an “outperform” rating and issued a $4.00 price target on shares of Mersana Therapeutics in a research note on Monday. Finally, Citigroup initiated coverage on Mersana Therapeutics in a research note on Friday, November 15th. They set a “buy” rating and a $5.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Mersana Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $4.25.

Mersana Therapeutics Stock Performance

Shares of MRSN stock opened at $0.51 on Wednesday. The company’s fifty day moving average price is $0.82 and its 200-day moving average price is $1.56. The stock has a market cap of $62.79 million, a PE ratio of -0.83 and a beta of 1.39. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 13.35. Mersana Therapeutics has a 12 month low of $0.46 and a 12 month high of $6.28.

Mersana Therapeutics (NASDAQ:MRSN) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.05. The company had revenue of $16.36 million for the quarter, compared to analysts’ expectations of $7.71 million. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%.

Institutional Investors Weigh In On Mersana Therapeutics

A number of institutional investors have recently made changes to their positions in the company. US Bancorp DE bought a new stake in shares of Mersana Therapeutics during the third quarter valued at approximately $31,000. Los Angeles Capital Management LLC boosted its stake in Mersana Therapeutics by 8.1% during the 3rd quarter. Los Angeles Capital Management LLC now owns 189,660 shares of the company’s stock valued at $358,000 after purchasing an additional 14,240 shares during the last quarter. GSA Capital Partners LLP boosted its stake in Mersana Therapeutics by 368.9% during the 3rd quarter. GSA Capital Partners LLP now owns 271,774 shares of the company’s stock valued at $514,000 after purchasing an additional 213,814 shares during the last quarter. Intech Investment Management LLC bought a new stake in shares of Mersana Therapeutics in the 3rd quarter worth $52,000. Finally, HealthInvest Partners AB raised its stake in shares of Mersana Therapeutics by 191.3% in the third quarter. HealthInvest Partners AB now owns 538,621 shares of the company’s stock worth $1,018,000 after purchasing an additional 353,721 shares during the last quarter. Hedge funds and other institutional investors own 93.92% of the company’s stock.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.